COVID-19 and cardiovascular system-a comprehensive review

Rev Cardiovasc Med. 2021 Jun 30;22(2):343-351. doi: 10.31083/j.rcm2202041.

Abstract

Coronavirus disease 2019 (COVID-19), a mystified cryptic virus has challenged the mankind that has brought life to a standstill. Catastrophic loss of life, perplexed healthcare system and the downfall of global economy are some of the outcomes of this pandemic. Humans are raging a war with an unknown enemy. Infections, irrespective of age and gender, and more so in comorbidities are escalating at an alarming rate. Cardiovascular diseases, are the leading cause of death globally with an estimate of 31% of deaths worldwide out of which nearly 85% are due to heart attacks and stroke. Theoretically and practically, researchers have observed that persons with pre-existing cardiovascular conditions are comparatively more vulnerable to the COVID-19 infection. Moreover, they have studied the data between less severe and more severe cases, survivors and non survivors, intensive care unit (ICU) patients and non ICU patients, to analyse the relationship and the influence of COVID-19 on cardiovascular health of an individual, further the risk of susceptibility to submit to the virus. This review aims to provide a comprehensive particular on the possible effects, either direct or indirect, of COVID-19 on the cardiovascular heath of an individual.

Keywords: ACE2; COVID-19; Cardiovascular disorders; Comorbidities.

Publication types

  • Review

MeSH terms

  • Antiviral Agents / therapeutic use
  • COVID-19 / mortality
  • COVID-19 / physiopathology
  • COVID-19 / therapy
  • COVID-19 / virology*
  • COVID-19 Drug Treatment
  • Cardiovascular Agents / therapeutic use
  • Cardiovascular Diseases / mortality
  • Cardiovascular Diseases / physiopathology
  • Cardiovascular Diseases / therapy
  • Cardiovascular Diseases / virology*
  • Cardiovascular System / drug effects
  • Cardiovascular System / physiopathology
  • Cardiovascular System / virology*
  • Comorbidity
  • Host-Pathogen Interactions
  • Humans
  • Prognosis
  • Risk Assessment
  • Risk Factors
  • SARS-CoV-2 / drug effects
  • SARS-CoV-2 / pathogenicity*

Substances

  • Antiviral Agents
  • Cardiovascular Agents